Ironwood Pharmaceuticals, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; unaudited. Comparisons are with Q1 2018 unless noted. Ironwood is focused on gastrointestinal medicines, with LINZESS/linaclotide its principal commercial product. The financial statements include Cyclerion through March 31; the tax-free spin-off of the sGC business closed April 1, 2019.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Total revenue | $68.7 million | $69.2 million; down 1% |
| Collaborative arrangements revenue | $66.2 million | $63.1 million; up 5% |
| API sales | $2.6 million | $5.4 million; down 53% |
| Operating expenses | $123.1 million | $105.0 million; up 17% |
| Operating loss | $(54.4) million | $(35.9) million |
| Net loss | $(59.3) million; $(0.38) per share | $(43.1) million; $(0.29) per share |
| Operating cash flow | $(42.4) million | $(30.9) million |
| Cash and cash equivalents at quarter-end | $119.0 million unrestricted | $173.2 million at Dec. 31, 2018 |
Revenue was primarily collaboration income from LINZESS. Ironwood’s share of U.S. LINZESS net profits was $54.0 million, versus $50.2 million a year earlier; management attributed the increase to higher prescription demand. No product revenue was reported in Q1 2019, following termination of the U.S. lesinurad license. API sales declined mainly because of lower shipments to Astellas in Japan.
Research and development expense rose 48% to $54.0 million, primarily due to early-stage pipeline spending and linaclotide development. Selling, general and administrative expense rose 9% to $64.7 million; separation-related costs were a major factor. The operating loss was approximately 79% of revenue. Gross margin was not presented as a key measure in the filing.
Quarter-end total cash, cash equivalents and restricted cash was $126.7 million. Cash declined $54.1 million during the quarter, including $42.4 million used in operations, $12.3 million of 2026 Notes principal payments and $3.2 million of capital expenditures, partly offset by stock-plan proceeds. Management stated that cash on hand was expected to fund projected operating needs for at least the next 12 months, while cautioning that actual cash use could be higher.
At March 31, principal indebtedness was approximately $473.4 million: $335.7 million of 2.25% convertible notes due 2022 and approximately $137.7 million remaining on 8.375% notes due 2026. The balance sheet carried these notes at lower amounts after discounts and other accounting adjustments. The 2026 Notes require quarterly payments linked to U.S. LINZESS sales; approximately $46.0 million was classified as current. Operating lease liabilities totaled $92.0 million after adoption of ASC 842.
Material changes and significant events
- U.S. LINZESS collaboration revenue increased with prescription demand, but lower Japanese API shipments and the end of lesinurad product sales offset that growth.
- The company completed the Cyclerion separation on April 1, after quarter-end. Cyclerion’s sGC programs and certain assets and liabilities transferred to the new company; Ironwood’s post-separation focus is GI medicines.
- Separation-related costs included an approximately $18.7 million increase in SG&A costs versus the prior year, including consulting and investment banking expenses. Accrued separation activities were approximately $8.7 million at March 31.
- Ironwood recorded $3.3 million in restructuring expense, associated mainly with a February 2019 workforce reduction of 35 employees.
- Adoption of lease accounting standard ASC 842 resulted in recognition of approximately $88.3 million of operating lease right-of-use assets and $94.9 million of lease liabilities at adoption. A $0.5 million data-center lease asset impairment was recorded in Q1.
Outlook, risks and contingencies
No specific revenue or earnings guidance was provided. Management expects continued investment in linaclotide and GI development programs, including MD-7246 for IBS-D and Phase III IW-3718 trials for persistent GERD. LINZESS received Chinese marketing approval for adults with IBS-C in January 2019. The filing states that Ironwood has not achieved positive operating cash flow and cannot predict when, or if, it will become profitable or cash-flow positive.
- Revenue concentration and execution: Ironwood depends substantially on U.S. LINZESS collaboration proceeds and on Allergan’s reporting, commercialization and cost-sharing performance. Demand, reimbursement, competition, partner execution and supply constraints could affect results.
- Debt and liquidity: Debt service depends in part on LINZESS-related cash receipts. The 2026 Notes have security and covenants; the 2022 Notes include conversion, repurchase and cross-default provisions. Cash sufficiency estimates are forward-looking.
- Generic litigation: Ironwood and Allergan are pursuing patent litigation against Teva and Sandoz concerning generic LINZESS applications. Trial was scheduled for June 2019; the applicable FDA approval stay was described as running to February 29, 2020, absent an adverse court decision or other adjustment. Ironwood had also settled with three other generic companies.
- Separation risks: The distribution was intended to qualify as tax-free, but tax treatment is not assured. The filing describes potential tax exposure, indemnification and transition-service risks, operational disruption, and management changes.
- Development and safety: Clinical outcomes and regulatory decisions for pipeline programs are uncertain. LINZESS has a boxed warning regarding pediatric use; common adverse reactions include diarrhea. Manufacturing, reimbursement, competitive and regulatory risks remain material.
- Lesinurad transition: Ironwood said it remained in discussions with AstraZeneca regarding costs associated with termination and transition; failure to agree could lead to administrative proceedings or litigation.
Management reported effective disclosure controls and procedures as of March 31, 2019, and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether U.S. LINZESS demand and Ironwood’s net-profit share continue to grow, and how Allergan’s commercial costs affect that share.
- Post-separation cash, expenses and debt-service needs, including the pace of 2026 Notes principal repayments and the stated 12-month liquidity outlook.
- Actual separation costs and any continuing transition-service, tax or indemnification obligations involving Cyclerion.
- Developments and outcomes in Teva and Sandoz patent litigation, including the scheduled trial and any effect on generic entry timing.
- Clinical, regulatory and funding progress for MD-7246, IW-3718 and post-approval linaclotide studies.